Accustem Sciences Inc.
ACUT - Insider Information
Get informed when a big investor buys or sells
+ FollowMarket Cap$2.15M
Close$
$-0.00
100.4% downside
Current Fair Value
100.4% downsideOvervalued by 100.4% based on the discounted cash flow analysis.
Insider Trades
Loading insider trades…
Congress Trades
Loading congress trades…
Share Statistics
| Market cap | $2.15 Million |
|---|---|
| Enterprise Value | $2.20 Million |
| Earnings per Share | $-0.12 |
| Beta | 1.89 |
| Outstanding Shares | 16,072,267 |
Return
| Return on Equity | 40.15% |
|---|---|
| Return on Assets | -102.92% |
| Return on Invested Capital | 42.54% |
Valuation & Multiples
| P/E Ratio | -1.26 |
|---|---|
| PEG | 3.39 |
| Price to Sales | - |
| Price to Book Ratio | -0.15 |
| Enterprise Value to Revenue | 22.33 |
| Enterprise Value to EBIT | -1.25 |
| Enterprise Value to Net Income | -2 |
| Total Debt to Enterprise | 0.03 |
| Debt to Equity | -0.02 |
Revenue Sources
No data
Last Earnings Call
Report Date
August 14, 2026
EPS Estimate
-
Consensus analyst estimateRevenue Estimate
-
Consensus analyst estimateInstitutional Sentiment (Put/Call)
No data available for the latest quarter.
Institutional Ownership
No data available for the latest quarter.
About Accustem Sciences Inc.
4 employees
CEO: Wendy E. Blosser
AccuStem Sciences, Inc. operates as a life science firm committed to improving the outlook for individuals battling cancer. Its primary innovation is the StemPrintER technology, an advanced multi-gene prognostic assay designed to predict...